PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)
Robert M. Rifkin(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Ralph V. Boccia(Center for Cancer and Blood Disorders), Habte Yimer(Texas Oncology), Roger M. Lyons(Hematology Oncology Associates), Lawrence E Dollar(Takeda (United States)), Brittany Demers(Millennium Engineering and Integration (United States)), Stephen J. Noga, P Kelly(New York City Health and Hospitals Corporation), Christopher A. Yasenchak(Willamette Valley Cancer Institute and Research Center), Ruemu Birhiray(The US Oncology Network), S. Manda(Arizona Oncology), B. Wang(Takeda (United States)), Presley Whidden(Millennium Engineering and Integration (United States)), Eric Chojnicki(Takeda (United States))
Cited by 1
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
|New England Journal of Medicine|2006|530
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425